Summit Therapeutics Inc. (NASDAQ: SMMT) stock jumped 1.59% on Monday to $4.46 against a previous-day closing price of $4.39. With 1.87 million shares changed hands, the volume of the stock remained lighter than its average volume of 9.41 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.7800 whereas the lowest price it dropped to was $4.2000. The 52-week range on SMMT shows that it touched its highest point at $5.78 and its lowest point at $0.66 during that stretch. It currently has a 1-year price target of $5.00. Beta for the stock currently stands at -1.00.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SMMT was down-trending over the past week, with a drop of -7.08%, but this was up by 20.54% over a month. Three-month performance surged to 271.67% while six-month performance rose 316.82%. The stock gained 100.00% in the past year, while it has gained 4.94% so far this year.
Float and Shares Shorts:
At present, 148.58 million SMMT shares are outstanding with a float of 34.00 million shares on hand for trading. On Oct 13, 2022, short shares totaled 0.37 million, which was 0.19% higher than short shares on Sep 14, 2022. In addition to Mr. Robert W. Duggan as the firm’s CEO & Exec. Chairman, Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA serves as its Co-CEO, Pres & Director.
Through their ownership of 4.18% of SMMT’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 113.98% of SMMT, in contrast to 1.24% held by mutual funds. Shares owned by individuals account for 0.35%. As the largest shareholder in SMMT with 0.39% of the stake, The Vanguard Group, Inc. holds 775,922 shares worth 775,922. A second-largest stockholder of SMMT, Millennium Management LLC, holds 431,560 shares, controlling over 0.21% of the firm’s shares. Morgan Stanley & Co. LLC is the third largest shareholder in SMMT, holding 339,737 shares or 0.17% stake. With a 0.46% stake in SMMT, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 929,216 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.22% of SMMT stock, is the second-largest Mutual Fund holder. It holds 444,791 shares valued at 1.89 million. iShares Biotechnology ETF holds 0.11% of the stake in SMMT, owning 225,892 shares worth 0.96 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SMMT since 1 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SMMT analysts setting a high price target of $4.00 and a low target of $4.00, the average target price over the next 12 months is $4.00. Based on these targets, SMMT could drop -10.31% to reach the target high and fall by -10.31% to reach the target low. Reaching the average price target will result in a decline of -10.31% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. SMMT will report FY 2021 earnings on 03/15/2024. Analysts have provided yearly estimates in a range of -$0.96 being high and -$0.96 being low. For SMMT, this leads to a yearly average estimate of -$0.96. Based on analyst estimates, the high estimate for the next quarter is -$0.27 and the low estimate is -$0.27. The average estimate for the next quarter is thus -$0.27.